Frontiers in Immunology (Nov 2023)

Experimental validation of immunogenic SARS-CoV-2 T cell epitopes identified by artificial intelligence

  • Lorenzo Federico,
  • Lorenzo Federico,
  • Brandon Malone,
  • Simen Tennøe,
  • Viktoriia Chaban,
  • Viktoriia Chaban,
  • Julie Røkke Osen,
  • Julie Røkke Osen,
  • Murat Gainullin,
  • Murat Gainullin,
  • Eva Smorodina,
  • Eva Smorodina,
  • Hassen Kared,
  • Hassen Kared,
  • Rahmad Akbar,
  • Rahmad Akbar,
  • Victor Greiff,
  • Victor Greiff,
  • Richard Stratford,
  • Trevor Clancy,
  • Ludvig Andre Munthe,
  • Ludvig Andre Munthe

DOI
https://doi.org/10.3389/fimmu.2023.1265044
Journal volume & issue
Vol. 14

Abstract

Read online

During the COVID-19 pandemic we utilized an AI-driven T cell epitope prediction tool, the NEC Immune Profiler (NIP) to scrutinize and predict regions of T cell immunogenicity (hotspots) from the entire SARS-CoV-2 viral proteome. These immunogenic regions offer potential for the development of universally protective T cell vaccine candidates. Here, we validated and characterized T cell responses to a set of minimal epitopes from these AI-identified universal hotspots. Utilizing a flow cytometry-based T cell activation-induced marker (AIM) assay, we identified 59 validated screening hits, of which 56% (33 peptides) have not been previously reported. Notably, we found that most of these novel epitopes were derived from the non-spike regions of SARS-CoV-2 (Orf1ab, Orf3a, and E). In addition, ex vivo stimulation with NIP-predicted peptides from the spike protein elicited CD8+ T cell response in PBMC isolated from most vaccinated donors. Our data confirm the predictive accuracy of AI platforms modelling bona fide immunogenicity and provide a novel framework for the evaluation of vaccine-induced T cell responses.

Keywords